HC Wainwright Reiterates “Neutral” Rating for RAPT Therapeutics (NASDAQ:RAPT)

RAPT Therapeutics (NASDAQ:RAPT)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports.

Other research analysts have also issued reports about the company. UBS Group lowered their price target on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research report on Monday, September 9th. Stifel Nicolaus restated a “hold” rating and set a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. Piper Sandler downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $8.00 to $2.00 in a research report on Monday, November 11th. Wells Fargo & Company dropped their price objective on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.50.

RAPT Therapeutics Trading Up 2.9 %

Shares of RAPT opened at $1.08 on Monday. The company’s 50-day moving average price is $1.84 and its 200 day moving average price is $2.67. RAPT Therapeutics has a 12-month low of $1.00 and a 12-month high of $27.35. The firm has a market cap of $37.76 million, a P/E ratio of -0.39 and a beta of 0.33.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. Equities research analysts forecast that RAPT Therapeutics will post -2.8 earnings per share for the current year.

Institutional Investors Weigh In On RAPT Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in RAPT. Acadian Asset Management LLC purchased a new position in RAPT Therapeutics in the first quarter valued at approximately $97,000. Readystate Asset Management LP acquired a new position in shares of RAPT Therapeutics in the 3rd quarter valued at $36,000. XTX Topco Ltd purchased a new position in shares of RAPT Therapeutics in the 2nd quarter valued at $108,000. Barclays PLC raised its stake in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after acquiring an additional 29,195 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its position in RAPT Therapeutics by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after acquiring an additional 3,824 shares during the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.